122 related articles for article (PubMed ID: 34596147)
21. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
de Wit R; Wülfing C; Castellano D; Kramer G; Eymard JC; Sternberg CN; Fizazi K; Tombal B; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Bono J
ESMO Open; 2021 Oct; 6(5):100241. PubMed ID: 34450475
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Armstrong AJ; Saad F; Phung D; Dmuchowski C; Shore ND; Fizazi K; Hirmand M; Forer D; Scher HI; Bono J
Cancer; 2017 Jun; 123(12):2303-2311. PubMed ID: 28171710
[TBL] [Abstract][Full Text] [Related]
23. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
Shigeta K; Kosaka T; Kitano S; Yasumizu Y; Miyazaki Y; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Tanoguchi H; Hasegawa S; Oya M
Ann Surg Oncol; 2016 Nov; 23(12):4115-4122. PubMed ID: 27364499
[TBL] [Abstract][Full Text] [Related]
24. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES
Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307
[TBL] [Abstract][Full Text] [Related]
25. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
26. Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients.
Kobayashi H; Shiota M; Sato N; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Anticancer Drugs; 2022 Jan; 33(1):e541-e547. PubMed ID: 34387597
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.
Yamashita S; Kohjimoto Y; Iguchi T; Koike H; Kusumoto H; Iba A; Kikkawa K; Kodama Y; Matsumura N; Hara I
BMC Urol; 2016 Mar; 16():13. PubMed ID: 27001073
[TBL] [Abstract][Full Text] [Related]
28. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
[TBL] [Abstract][Full Text] [Related]
29. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
30. C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer.
Liao SG; Cheng HH; Lei Y
Oncol Res Treat; 2016; 39(5):266-71. PubMed ID: 27174032
[TBL] [Abstract][Full Text] [Related]
31. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
32. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
33. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
34. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
35. Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Strauss A; Worst TS; Nuhn P; Bolenz C; Heinrich E
Urol Int; 2017; 99(4):414-421. PubMed ID: 28700990
[TBL] [Abstract][Full Text] [Related]
36. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
Kosaka T; Hongo H; Watanabe K; Mizuno R; Kikuchi E; Oya M
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1061-1066. PubMed ID: 30283980
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory factor-based prognostic risk stratification for patients with metastatic castration-resistant prostate cancer treated with docetaxel.
Shi X; Fan J; Pei X; Wang Y; Guo G; Yang T; Wang X; He D; Li L
Andrologia; 2021 Jul; 53(6):e14064. PubMed ID: 33900646
[TBL] [Abstract][Full Text] [Related]
38. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.
Templeton AJ; Pezaro C; Omlin A; McNamara MG; Leibowitz-Amit R; Vera-Badillo FE; Attard G; de Bono JS; Tannock IF; Amir E
Cancer; 2014 Nov; 120(21):3346-52. PubMed ID: 24995769
[TBL] [Abstract][Full Text] [Related]
39. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
40. Association of Hyponatremia With Survival in Patients With Castration-resistant Prostate Cancer: A Clinical Commentary.
Stangl-Kremser J; Kramer G; Shariat SF
Clin Genitourin Cancer; 2019 Dec; 17(6):e1188-e1192. PubMed ID: 31623929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]